KLINIChESKIE PREIMUShchESTVA PERVOGO ANALOGA ChELOVEChESKOGO GPP-1 LIRAGLUTIDA PRI LEChENII BOL'NYKh SAKhARNYM DIABETOM 2 TIPA


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Hypoglycemic agents, the mechanism of action of which is based on the effects of incretins, represent totally new and unique class of drugs providing pathogenetically relevant complex therapeutic approach to the treatment of patients with type 2 diabetes mellitus. Currently, results of completed clinical studies and experience in application in clinical practice have shown convincingly that liraglutide ( Victoza®) is the most effective and safe drug for the achievement of goals of therapy in patients with type 2 diabetes mellitus at early stages of treatment. The potentials for the effective and permanent weight loss when using liraglutide is an important argument in favor of its administration during choice of therapy in DM2 patients with overweight or obesity.

Full Text

Restricted Access

About the authors

I. Yu Demidova

References

  1. Intensive blood-glucose control with sulpho-nylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study Group. Lancet 1998;352(9131):837-53.
  2. Khaw K, Wareham N, Bingham S, et al. Association of Hemoglobin A1c with Cardiovascular Disease and Mortality in Adults: The European Prospective Investigation into Cancer in Norfolk. Annals of Internal Medicine 2004;141(6):413-21.
  3. La Barre J. Sur les possibilites d'un traitement du diabete par l'incretine. Bull Acad R Med Belg 1932;12:620-34.
  4. Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 1967; 46(12):1954-62.
  5. Inzucchi S.E., Bergenstal R.M., Buse J.B, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2009;55:1577-96.
  6. Алгоритмы специализированной медицинской помощи больным сахарным диабетом (5-й выпуск). Под ред. И.И. Дедова, М.В. Шестаковой. Сахарный диабет 2011. № 4 Прил. 72 с.
  7. Niswender K, Pi-Sunyer X, Buse J, et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes, Obesity and Metabolism 2013;15:42-54.
  8. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-78.
  9. Nauck MA, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). The LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 2009;32:84-90.
  10. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, paralleltreatment trial. Lancet 2009;373:473-81.
  11. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human GLP-1 analogue liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009;32:1224-30.
  12. Russell-Jones D, Vaag A, Schmitz O, et al; on behalf of the LEAD-5 met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulphonyl-urea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 met+SU). Diabetologia 2009; 52:2046-55.
  13. Buse JB, Rosenstock J, Sesti G, et al; for the LEAD 6 Study Group. A study of two glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: liraglutide once daily compared with exenatide twice daily in a randomised, 26-week, open-label trial (LEAD-6). Lancet 2009;374:39-47.
  14. Pratley RE, Nauck M, Bailey T, et al; for the 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin in patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week,randomised, parallel-group, open-label trial. Lancet 2010;375:1447-56.
  15. Buse JB, Sesti G, Schmidt WE, et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes care 2010;33(6):1300-3.
  16. Pratley RE, et al. Diabetes 2011:60(Suppl. 1):1119.
  17. Henry RR, Buse JB, Sesti G, et al. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A1c: a meta-analysis of the liraglutide development program. Endocr Pract 2011;17(6):906-13.
  18. Holst JJ, Nauck M, Brett J, Falahati A, Pratley R. Improvement in glycaemic control when adding liraglutide to existing therapy: results from a meta-analysis of six large randomised clinical trials. Diabetologia 2009;52(Suppl. 1):288.
  19. Nauck MA, Vaag A, Colagiuri S, et al. HbA1c reduction with liraglutide in type diabetes patients is associated with initial HbA1c levels. International Diabetes Federation - 20th World Diabetes Congress 2009;1400.
  20. Fakhoury WK, Lereun C, Wright D. A metaanalysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 2010;86:44-57.
  21. Vilsbll T, Christensen M, Junker AE, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012 344:d7771 doi:10.1136/ bmj.d7771.
  22. Gilbert MP, Pratley RE. Efficacy and safety of incretin-based therapies in patients with type diabetes mellitus. The American Journal of Medicine 2009;122(6A):11-24.
  23. Karagiannis T, Paschos P, Paletas K, et al. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012;344:e1369 doi: 10.1136/bmj. e1369 (Published 12 March 2012).
  24. Zinman B, Colagiuri S, Madsbad S, et al. The human GLP-1 analog, liraglutide, improves BMI and waist circumference in patients with type 2 diabetes: meta-analysis of six phase trials. Diabetes 2010;59(Suppl. 1):A495 (1894).
  25. Fonseca V, Madsbad S, Falahati A, et al. Once daily human GLP-1 analog liraglutide reduces systolic blood pressure: a meta-analysis of six clinical trials (LEAD). Diabetes 2009;58(Suppl. 1):A146.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies